Evernow BBB and Consumer-Complaint Trends: What the Data Actually Show

Is Evernow Legit? Licensing and Regulatory Standing

Evernow operates as a licensed telehealth entity, and its prescribers hold active state medical licenses required by applicable state medical boards. No FDA warning letters or FTC consent orders specifically naming Evernow appear in the public record as of January 2025. That baseline matters, but licensing alone does not settle questions about care quality or business practices.

Ryan Haight Act and Prescribing Authority

Federal telemedicine prescribing of controlled substances is governed by the Ryan Haight Online Pharmacy Consumer Protection Act of 2008 [1]. Estrogen and progesterone are not Schedule II-V controlled substances, so Evernow prescribers are not bound by the in-person evaluation requirement for those hormones. Testosterone, when prescribed for women, may carry Schedule III classification depending on formulation, triggering stricter rules [2].

State Medical Board Oversight

Each prescriber on a telehealth platform must hold a license in the patient's state. The Federation of State Medical Boards maintains an online license verification tool, and consumers can confirm individual provider standing there [3]. No state board disciplinary actions specifically tied to the Evernow platform appeared in a January 2025 review of publicly available board records.

LegitScript Classification

LegitScript, which certifies online pharmacies and telehealth platforms for compliance, had not granted Evernow a "Certified" designation as of January 2025. That absence does not equal illegality, but certified status does signal a higher tier of verified compliance. Consumers comparing platforms should treat LegitScript certification as a positive differentiator [4].

BBB Profile and Complaint Volume

The Better Business Bureau profile for Evernow shows the company is not BBB-accredited as of January 2025. The BBB assigns ratings based on complaint history, time in business, transparent business practices, and licensing. A non-accredited status does not indicate active fraud, but it means the company has not undergone the BBB's voluntary accreditation review.

Complaint Categories

Consumer complaints filed with the BBB against Evernow cluster into three areas:

• Billing and collections. Charges appearing after a cancellation request is the most frequently cited issue. Several complainants described a gap of one to three billing cycles between a cancellation request and the final charge.
• Delivery or service issues. Delays in prescription forwarding to pharmacies, and difficulties reaching a prescriber for follow-up questions, appear in multiple filings.
• Refund disputes. Requests for partial refunds on unused subscription periods report slow or absent responses from customer service.

The BBB's complaint resolution process asks businesses to respond within 14 days. Response rates and resolution quality for Evernow are visible on the live BBB profile page; consumers should check the current record directly, as volumes change month to month.

How This Compares to Sector Peers

Direct-to-consumer telehealth complaint patterns broadly mirror what Evernow shows. A 2022 Federal Trade Commission staff report on subscription billing practices found that unclear cancellation terms, automatic renewals, and post-cancellation charges were the top three billing complaints across subscription services in health and wellness [5]. Evernow's complaint profile fits that sector-wide pattern rather than indicating a uniquely problematic operation.

Consumer Reviews Beyond the BBB

Trustpilot and App Store Signals

Platform reviews on Trustpilot and the Apple App Store (as of January 2025) show a bimodal distribution. Positive reviews consistently highlight convenient access to menopause-trained clinicians, faster prescription turnaround than a primary care visit, and patient satisfaction with estradiol and progesterone management. Negative reviews repeat the BBB themes: billing persistence after cancellation, and limited synchronous access to prescribers.

What FTC Rules Require

The FTC's updated Negative Option Rule, finalized in 2024, requires that cancellation must be at least as easy as sign-up [6]. A company offering one-click enrollment must provide one-click cancellation. Complaints about cancellation difficulty, if substantiated, would put Evernow in potential conflict with that rule. The FTC accepts complaints at ftc.gov/complaint, and consumers who experience post-cancellation charges should file there in addition to the BBB.

Clinical Quality Benchmarks: What Good Menopause Telehealth Looks Like

Evernow's marketing positions it as a menopause specialist platform. Evaluating that claim requires comparing its protocols against established clinical standards.

2023 Menopause Society Guidelines

The Menopause Society (formerly NAMS) 2023 position statement states: "Hormone therapy remains the most effective treatment for vasomotor symptoms and is acceptable for healthy symptomatic women who are younger than 60 years or within 10 years of menopause onset" [7]. A compliant telehealth platform should screen candidates against that age and timing criterion, assess cardiovascular and breast cancer risk, and document the shared decision-making process.

First-Line Hormone Regimens

FDA-approved systemic HRT regimens for menopause include:

• Oral estradiol (0.5 mg to 2 mg daily) combined with micronized progesterone 100 mg to 200 mg for women with a uterus [8].
• Transdermal estradiol patches (0.025 mg/day to 0.1 mg/day) as an alternative with potentially lower venous thromboembolism risk compared to oral formulations, per data from the ESTHER study [9].
• Vaginal estradiol (0.01% cream, 10 mcg insert) for genitourinary syndrome of menopause where systemic symptoms are absent [10].

Platforms prescribing these agents should follow the FDA-approved labeling and should not prescribe compounded bioidentical hormones as a first-line substitution without documented clinical rationale, per FDA guidance on compounded drug products [11].

Compounded Hormones: Specific Risks

Some telehealth platforms, including Evernow, have offered compounded bioidentical hormone preparations. The FDA does not evaluate compounded products for safety or efficacy before dispensing. The Menopause Society's 2022 statement on compounded hormones says: "There is a lack of evidence regarding safety and efficacy of compounded hormone therapy, and women should be informed of the risks" [12]. Patients receiving compounded preparations from any telehealth platform should ask the prescriber for the clinical rationale and for information about the compounding pharmacy's 503A or 503B registration status [13].

The HealthRX Menopause Telehealth Evaluation Framework

When assessing any menopause telehealth platform, clinicians on the HealthRX medical team apply a five-point checklist:

1. Prescriber licensure: Verify active state license for the patient's state via the FSMB directory [3].
2. Guideline alignment: Confirm the platform screens for the Menopause Society's age and timing criteria before prescribing systemic HRT [7].
3. Compounding transparency: If compounded products are offered, confirm the pharmacy is 503A- or 503B-registered with the FDA [13].
4. Cancellation compliance: Test that cancellation requires no more steps than enrollment, per FTC Negative Option Rule [6].
5. Follow-up cadence: Ensure the platform offers at least one clinician follow-up visit within 90 days of initiating HRT, consistent with standard of care monitoring for symptom control and side effects.

Menopause Symptom Burden: Why Access to Care Matters

Approximately 1.3 million U.S. Women reach natural menopause each year, according to CDC data [14]. Vasomotor symptoms (hot flashes, night sweats) affect 75% of menopausal women and can persist for a median of 7.4 years, according to the SWAN study published in JAMA Internal Medicine [15]. Genitourinary symptoms affect up to 45% of postmenopausal women and are underreported to clinicians [16].

Access gaps are real. A 2021 survey published in Menopause found that only 31% of OB-GYN residency programs required formal menopause medicine training [17]. Telehealth platforms that fill that access gap provide genuine clinical value. The question is whether the business practices match the clinical mission.

The Cost Equation

Most insurance plans cover FDA-approved HRT when prescribed through an in-network provider. Evernow's cash-pay model means patients pay the platform subscription fee plus the cost of the prescription. Patients who have insurance coverage for HRT through an in-network gynecologist or internist trained in menopause medicine may find the total out-of-pocket cost lower outside a cash-pay telehealth subscription. The Menopause Society's "Find a Provider" tool can identify nearby menopause-trained clinicians [18].

Cardiovascular and Cancer Safety Context

The Women's Health Initiative (WHI) 2002 results caused a sharp decline in HRT use. Subsequent re-analysis changed the picture substantially. The 2017 WHI re-analysis by Manson et al., published in JAMA, found that conjugated equine estrogen plus medroxyprogesterone acetate initiated within 10 years of menopause was associated with a non-significant trend toward reduced all-cause mortality [19]. That finding supports the "timing hypothesis" now embedded in the Menopause Society 2023 guidelines [7].

Breast Cancer Risk Specifics

The absolute breast cancer risk increase with combined estrogen-progestogen therapy is approximately 1 additional case per 1,000 women per year of use, based on the 2019 Collaborative Group meta-analysis in The Lancet (N=108,647) [20]. Estrogen-only therapy in women without a uterus showed no significant increase in breast cancer incidence in the WHI estrogen-alone trial at 7.1 years of follow-up [21]. Patients should receive this quantified risk information during shared decision-making, regardless of whether care is delivered in-person or via telehealth.

Venous Thromboembolism Risk

The ESTHER case-control study found that oral estrogen carried a significantly higher VTE risk than transdermal estrogen (adjusted odds ratio 4.2 vs. 0.9 for transdermal), a finding replicated by the E3N cohort [9]. Any telehealth platform prescribing oral estradiol should screen for VTE risk factors including prior clot history, Factor V Leiden, obesity (BMI >30), and immobility.

What to Do If You Have a Complaint Against Evernow

Patients with unresolved billing disputes or care concerns have several formal options:

1. File with the BBB. The BBB complaint process is public and creates a documented resolution timeline.
2. File with the FTC. Use ftc.gov/complaint for subscription billing issues, especially post-cancellation charges [6].
3. File with your state medical board. If the concern involves clinical care quality, prescribing errors, or unlicensed practice, the relevant state medical board is the correct authority [3].
4. File with your state attorney general. Consumer protection divisions of state AG offices handle deceptive billing practices.
5. Dispute charges with your bank or credit card issuer. For unauthorized post-cancellation charges, a chargeback is a legitimate consumer remedy.

Practical Checklist Before Enrolling in Any Menopause Telehealth Platform

• Confirm the prescriber holds a current license in your state.
• Ask whether the platform follows the Menopause Society 2023 guidelines for HRT candidate selection [7].
• Understand exactly what the subscription covers and how cancellation works before providing payment information.
• If compounded hormones are offered, ask for the compounding pharmacy's FDA registration number [13].
• Request a written record of your prescription and the clinical rationale so you can share it with any other provider.
• Verify whether a follow-up visit is included within 90 days of starting therapy.